This Big New Development Could Be Bullish for Kenvue Stock

Starboard Value, the activist investing group that's making waves thanks to its new $1 billion stake in Pfizer, now also has a position in the consumer healthcare business Kenvue (NYSE: KVUE). The group will seek to engage with management and propose changes to the company's operations with the aim of unlocking better returns for shareholders than the stock's 10.5% loss since its spinoff from Johnson & Johnson in 2023.The activist's stake carries a handful of implications that are important for investors to understand. But at this early stage, the outlook appears to be moderately optimistic. Let's explore why.Kenvue is a notable healthcare player because it owns the rights to many common brands, including Neutrogena, Tylenol, Listerine, Band-Aid, Aveeno, Zyrtec, and others.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool